PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

KDIGO Consensus Reframes Kidney Function Changes in Heart Failure

This KDIGO Controversies Conference report clarifies how renal pharmacists should interpret creatinine shifts and deploy overlapping cardiorenal therapies in patients with concurrent heart failure and chronic kidney disease.
📅 Journal publication: Jun 2026 (online Mar 6, 2026) · Last updated: Jul 16, 2026
SGLT2 inhibitorsfinerenoneGLP-1 receptor agonistsARNIRAAS inhibitorsmineralocorticoid receptor antagonistschronic kidney diseaseheart failureHFpEFHFrEFcardiorenal syndromeKDIGOconsensus statementnatriuretic peptidesdiuretics Nephrology / Renal Pharmacy

Background Information

CKD and HF coexistence demands integrated management strategies.

Chronic kidney disease (CKD) and heart failure (HF) often coexist, increasing patient risks and complicating management. Emerging therapies like sodium-glucose cotransporter-2 inhibitors show promise, but evidence in advanced CKD is limited. Guideline-recommended therapies for HF causing minor kidney function decline should generally not be discontinued. CKD and HF management requires a nuanced, integrated approach.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Lam CSP, Bozkurt B, Cherney DZI, Ezekowitz JA, Jardine MJ, Khan SS, Madero M, Sarnak MJ, Ter Maaten JM, Cheung M, King JM, Grams ME, Jadoul M, Bansal N, Conference Participants

Citation: Lam CSP, Bozkurt B, Cherney DZI, et al. Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney international. 2026;109(6):1095-1113. doi:10.1016/j.kint.2025.10.011

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.